Role of Hyperglycemia-Induced Advanced Glycation End Product (AGE) Accumulation in Atherosclerosis

Sho-ichi Yamagishi, MD, PhD and Takanori Matsui, PhD

There is a growing body of evidence that cumulative hyperglycemic exposure plays a central role in the development and progression of atherosclerotic cardiovascular disease in diabetic patients. Monosaccharides, such as glucose, fructose, and glyceraldehyde can react non-enzymatically with amino groups of proteins, lipids, nucleic acids to form senescent macromolecules termed advanced glycation end products (AGEs), whose formation and accumulation has been known to progress in diabetic patients, especially in those with a long history of disease. The sustained accumulation of AGEs could contribute to the phenomenon of metabolic memory or legacy effects observed in long-term follow-up clinical studies of diabetic patients. AGE modification alters the structural integrity and function of various types of macromolecules, and interaction of AGEs with a receptor for AGEs (RAGE) has been shown to evoke inflammatory and thrombotic reactions. Therefore, the AGE–RAGE axis is a novel therapeutic target of atherosclerotic cardiovascular disease in diabetic patients. In this paper, we briefly review the pathological role of AGEs and their receptor RAGE system in atherosclerotic cardiovascular disease, including peripheral artery disease and discuss the clinical utility of measuring AGEs in evaluating the severity of atherosclerosis in patients with diabetes.

Keywords: AGEs, atherosclerosis, RAGE, PAD

Introduction

Atherosclerotic cardiovascular disease (CVD), such as acute myocardial infarction, stroke, and peripheral artery disease (PAD) is a highly prevalent complication of diabetes, and is also a leading cause of death in diabetic patients.1–12) More than 50% of diabetic patients have been shown to die from CVD in industrialized countries, and the risk of limb amputation due to PAD is increased dramatically in patients with diabetes.1–12) Furthermore, there is accumulating evidence that, in the development and progression of atherosclerotic CVD, including PAD in diabetes, cumulative hyperglycemic exposure plays a central role.2–6) Indeed, in contrast to the previous report of Haffner et al.,1) two clinical studies have shown that the risk of CVD in newly identified diabetic subjects or patients with a relatively short history of diabetes is not equivalent to non-diabetic individuals with a previous history of CVD, while patients with a more than 8 years history of diabetes had a comparable risk.2,3) In addition, the association of diabetes with the increased risk of CVD death was significantly attenuated after adjusting for HbA1c, but not lipid parameters, body mass index, inflammatory biomarkers, or systolic blood pressure.4) Monosaccharides, such as glucose, fructose, and glyceraldehyde can react non-enzymatically react with amino groups of proteins, lipids, nucleic acids to form senescent macromolecules termed advanced glycation end products (AGEs), whose formation and accumulation has been known to progress in diabetic patients, especially in those with a long history of disease.13–25) Since AGE-modified macromolecules are hardly metabolized and eliminated from the body, formation and accumulation of AGEs could reflect cumulative hyperglycemic exposure in patients with diabetes.13–25) Moreover, AGEs increase oxidative stress generation in various kinds of cells through the interaction with a cell surface receptor, receptor for AGEs (RAGE) and resultantly induce RAGE expression.13–25) Therefore, AGEs could cause the sustained activation of RAGE-signaling pathways and further stimulate the topical formation and accumulation of AGEs, thus, forming
a positive feedback loop, which may also account for the phenomenon of metabolic memory or legacy effects observed in long-term follow-up clinical studies of diabetic patients. These observations suggest that the AGE–RAGE axis is a novel therapeutic target of atherosclerotic CVD in patients with diabetes. Therefore, in this paper, we briefly review the pathological role of AGEs and their receptor RAGE system in atherosclerotic CVD, including PAD and discuss the clinical utility of measuring AGEs in evaluating the severity of atherosclerosis in patients with diabetes.

Role of AGEs and RAGE Axis in Atherosclerosis

The modification of AGE alters the structural integrity and function of various types of macromolecules, and the interaction of AGEs with RAGE evokes oxidative stress, inflammatory, thrombotic and fibrotic reactions in numerous kinds of cells, thereby, becoming involved in atherosclerotic CVD.

Endothelial dysfunction and vascular inflammation

Endothelial cell-derived nitric oxide (NO) plays a protective role against atherosclerosis; not only does it stimulate vasodilation, but it also inhibits inflammatory reactions, platelet activation and aggregation. Impaired endothelial cell-derived NO synthesis and/or bioavailability could contribute to endothelial dysfunction, an early characteristic feature of atherosclerosis, which could predict future cardiovascular events in high-risk patients such as diabetic subjects.

AGEs have been shown to inhibit endothelial cell-derived NO production via the suppression of endothelial NO synthase expression. In addition, the AGE–RAGE-induced oxidative stress generation could activate NO, resulting in the increased formation of toxic byproduct of NO, peroxynitrite. Furthermore, the interaction of AGEs with RAGE stimulates the generation of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthase in endothelial cells, mesangial cells, and renal proximal tubular cells. The circulating levels of AGEs have been associated with ADMA and/or endothelial dysfunction in high-risk patients for CVD, including end-stage renal failure patients with diabetes.

Accumulating evidence has suggested that atherosclerosis is intrinsically an inflammatory disease. Vascular inflammation could also play a role in endothelial dysfunction, and circulating levels of high-sensitivity C-reactive protein, an inflammatory biomarker have been shown to predict future adverse cardiovascular events in humans independent of conventional risk factors.

The engagement of RAGE with AGEs evokes oxidative stress and inflammatory reactions in vascular wall cells and, subsequently, elicits the activation of NF-κB, which could promote vascular inflammation. We have found that the serum levels of AGEs are correlated with inflammatory biomarkers such as monocyte chemoattractant protein-1 and soluble form of vascular cell adhesion molecule-1 in type 2 diabetic patients and independently associated with vascular inflammation evaluated by [18F]-fluorodeoxyglucose-positron emission tomography.

The tissue accumulation levels of AGEs can be evaluated non-invasively by skin autofluorescence (SAF) over the entire 420–600 nm emission spectrum to that over 300–420 nm with a desktop computer. SAF was inversely associated with anti-oxidative capacity of high-density lipoprotein in patients with type 2 diabetes, and were independently correlated with high-sensitivity C-reactive protein levels in patients on hemodialysis. These observations suggest further the pathological role of AGE accumulation in oxidative stress and inflammatory reactions in diabetes.

Arterial stiffness

Cross-linking by AGEs of extracellular matrix proteins such as collagens and elastin has been shown to contribute to arterial stiffness, a predictor of future cardiovascular events in both apparent healthy subjects and high-risk patients for CVD. Furthermore, SAF was independently correlated with aortic pulse wave velocity, a marker of arterial stiffness in type 1 diabetic patients without a history of CVD.

Plaque formation and angiogenesis

AGE modification of apolipoprotein B100 makes low-density lipoprotein more atherogenic. Moreover, the AGE–RAGE-induced oxidative stress has been shown to decrease the expression levels of adenosine triphosphate-binding membrane cassette transporter A1 (ABCA1) and ABCG1 in cultured macrophages and resultantly suppress cholesterol efflux from macrophages to apolipoprotein A1 and high-density lipoprotein, respectively. These observations suggest that the activation of the AGE–RAGE axis not only promotes the atherosclerotic plaque formation, but also impairs the reverse cholesterol transport, thereby, being involved in accelerated atherosclerosis in diabetes.

We have found previously that AGEs induce pathological angiogenesis by stimulating the autocrine production of vascular endothelial growth factor through the interaction of RAGE. Plaque angiogenesis could function as conduits for the entry of inflammatory cells into the atherosclerotic lesions, and are associated with plaque instability such as plaque rupture and intraplaque hemorrhage. Furthermore, recently, SAF has been shown to...
be associated with plaque vulnerability assessed by optical coherence tomography in patients with CVD. These findings suggest the active contribution of AGE–RAGE axis to atherosclerotic plaque instability in diabetes.

**Platelet activation, thrombosis, and hypercoagulability**

The interaction of AGEs with RAGE inhibits an antithrombotic prostanoid, prostacyclin production by endothelial cells, while it stimulates plasminogen activator inhibitor-1 generation and activity, thereby, stabilizing the arterial thrombi. In addition, AGEs have been shown to induce platelet activation and aggregation and enhance the coagulation cascade, which in concert could play a crucial role in the development of atherothrombotic CVD in diabetes.

**Impaired endothelial cell repair**

By inducing the apoptotic cell death of endothelial progenitor cells (EPCs) and simultaneously suppressing their migration and tube formation in vitro, the AGE–RAGE interaction could impair endothelial cell repair. Moreover, we have found previously that the serum levels of AGEs are inversely associated with the number and migratory activity of EPCs in healthy volunteers. Given that the reduced number and migratory activity of EPCs could be a predictor of future cardiovascular events, the AGE–RAGE axis may contribute to the increased risk of CVD partly via the impairment of endothelial cell repair. SAF has been reported to be independently associated with the decreased number of circulating EPCs in end-stage renal disease patients.

**AGEs as a Biomarker of CVD**

SAF was significantly higher in the PAD patients than the controls, especially in the PAD patients with cardiovascular comorbidity. Furthermore, SAF has been shown to be an independent predictor of amputation due to critical limb ischemia and is also associated with 5-year mortality and fetal and non-fetal major cardiovascular events in patients with PAD.

Circulating levels of pentosidine, one of the well characterized AGEs, were significantly higher in diabetic patients with PAD compared with non-diabetic individuals, and were inversely associated with ankle–brachial index. Moreover, pentosidine and carboxymethyllysine levels were correlated with the severity of PAD and independently associated with the presence of critical limb ischemia. SAF was elevated in patients with ST-elevation myocardial infarction and could be a predictor of future major adverse cardiac events in these patients. SAF was also correlated with cumulative diabetic exposure and cardiovascular mortality in patients with diabetes. The circulating levels of AGEs have been reported to predict total and cardiovascular disease mortality in both type 1 and type 2 diabetic patients.

**Conclusion**

Here, we briefly reviewed the role of AGE–RAGE axis in the development and progression of atherosclerotic CVD, including PAD. The inhibition of the AGE–RAGE axis may be a therapeutic target for CVD in diabetes.

**Acknowledgments**

This study was supported in part by Grants-in-Aid for Scientific Research (Grant Number 17K08968) from the Ministry of Education, Culture, Sports, Science and Technology, Japan (to SY).

**Disclosure Statement**

There is no conflict of interest in this paper.

**Author Contributions**

Study conception and design: SY
Initial draft writing: SY
Data integrity: SY
Data analysis accuracy: SY
Critical review of intellectual content: TM
Final approval of the manuscript: all authors

**References**

1) Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
2) Wannamethee SG, Shaper AG, Whincup PH, et al. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med 2011; 171: 404-10.
3) Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 2002; 324: 939.
4) Rao Kondapally Seshasai S, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829-41.
5) Yamagishi SI, Nakamura N, Matsui T. Glycation and cardiovascular disease in diabetes: a perspective on the concept of metabolic memory. J Diabetes 2017; 9: 141-8.
11) Shammas AN, Jeon-Slaughter H, Tsai S, et al. Major limb arterial disease in diabetes-a review. Diabet Med 2010; 27: 4-14.
10) Yang SL, Zhu LY, Han R, et al. Pathophysiology of peripheral arterial disease in diabetes mellitus. J Diabetes 2017; 9: 133-40.
9) JUDE EB, Eleftheriadou I, Tentolouris N. Peripheral arterial disease in diabetes: review. Diabet Med 2010; 27: 1120-2.
8) Melton LJ 3rd, Macken KM, Palumbo PJ, et al. Incidence and prevalence of clinical peripheral vascular disease in a population-based cohort of diabetic patients. Diabetes Care 1980; 3: 650-4.
7) Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc 1985; 33: 13-8.
6) Yamagishi S, Nakamura N, Suematsu M, et al. Advanced glycation endproducts (AGEs) as long-term markers of glycemic damage and risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002; 25: 894-9.
5) Monnier VM, Genuth S, Sell DR. The pecking order of skin Advanced Glycation Endproducts (AGEs) as long-term markers of glycemic damage and risk factors for micro- and subclinical macrovascular disease progression in Type 1 diabetes. Glycoconj J 2016; 33: 569-79.
4) Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11: 2279-99.
3) Schmidt AM. 2016 ATVB plenary lecture: receptor for advanced glycation endproducts and implications for the pathogenesis and treatment of cardiometabolic disorders: spotlight on the macrophage. Arterioscler Thromb Vasc Biol 2017; 37: 613-21.
2) Yamagishi S. Potential clinical utility of advanced glycation end product cross-link breakers in age- and diabetes-associated disorders. Rejuvenation Res 2012; 15: 564-72.
1) Vlassara H, Striker GE. Advanced glycation endproducts in diabetes and diabetic complications. Endocrinol Metab Clin North Am 2013; 42: 697-719.

7) Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc 1985; 33: 13-8.
8) Melton LJ 3rd, Macken KM, Palumbo PJ, et al. Incidence and prevalence of clinical peripheral vascular disease in a population-based cohort of diabetic patients. Diabetes Care 1980; 3: 650-4.
9) JUDE EB, Eleftheriadou I, Tentolouris N. Peripheral arterial disease in diabetes: review. Diabet Med 2010; 27: 4-14.
10) Yang SL, Zhu LY, Han R, et al. Pathophysiology of peripheral arterial disease in diabetes mellitus. J Diabetes 2017; 9: 133-40.
11) Shammas AN, Jeon-Slaughter H, Tsai S, et al. Major limb outcomes following lower extremity endovascular revascularization in patients with and without diabetes mellitus. J Endovasc Ther 2017; 24: 376-82.
12) Adler AI, Stevens RJ, Neil A, et al. UKPDS59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002; 25: 894-9.
13) Monnier VM, Genuth S, Sell DR. The pecking order of skin Advanced Glycation Endproducts (AGEs) as long-term markers of glycemic damage and risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002; 25: 894-9.
14) Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11: 2279-99.
15) Schmidt AM. 2016 ATVB plenary lecture: receptor for advanced glycation endproducts and implications for the pathogenesis and treatment of cardiometabolic disorders: spotlight on the macrophage. Arterioscler Thromb Vasc Biol 2017; 37: 613-21.
16) Yamagishi S. Potential clinical utility of advanced glycation end product cross-link breakers in age- and diabetes-associated disorders. Rejuvenation Res 2012; 15: 564-72.
17) Vlassara H, Striker GE. Advanced glycation endproducts in diabetes and diabetic complications. Endocrinol Metab Clin North Am 2013; 42: 697-719.
18) Ward MS, Fotheringham AK, Cooper ME, et al. Targeting advanced glycation endproducts and mitochondrial dysfunction in cardiovascular disease. Curr Opin Pharmacol 2013; 13: 654-61.
19) Yamagishi S, Nakamura N, Suematsu M, et al. Advanced glycation end products: a molecular target for vascular complications in diabetes. Mol Med 2015; 21 Suppl 1: S32-40.
20) Berezin A. Metabolic memory phenomenon in diabetes mellitus: achieving and perspectives. Diabetes Metab Syndr 2016; 10 Suppl 1: S176-83.
21) Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-53.
22) Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up. Diabetes Care 2016; 39: 686-93.
23) Orchard TJ, Nathan DM, Zinman B, et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 2015; 313: 45-53.
24) Monnier VM, Sun W, Gao X, et al. Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes. Cardiovasc Diabetol 2015; 14: 118.
25) Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89.
26) Cooke JP, Dzau VJ. Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular diseases. Circulation 1997; 96: 379-82.
27) Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997; 100: 2153-7.
28) Zoccali C. The endothelium as a target in renal diseases. J Nephrol 2007; 20 Suppl 12: S39-44.
29) Persson F, Rossing P, Hovind P, et al. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. Scand J Clin Lab Invest 2008; 68: 731-8.
30) Perticone F, Maio R, Perticone M, et al. Endothelial dysfunction and subsequent decline in glomerular filtration rate in hypertensive patients. Circulation 2010; 122: 379-84.
31) Ueda S, Yamagishi S, Okuda S. New pathways to renal damage: role of ADMA in retarding renal disease progression. J Nephrol 2010; 23: 377-86.
32) Ueda S, Yamagishi S, Yokoro M, et al. Role of asymmetric dimethylarginine in cardiorenal syndrome. Curr Pharm Des 2014; 20: 2448-55.
33) Nakayama Y, Ueda S, Yamagishi S, et al. Asymmetric dimethylarginine accumulates in the kidney during ischemia/reperfusion injury. Kidney Int 2014; 85: 570-8.
34) Yokoro M, Nakayama Y, Yamagishi S, et al. Asymmetric dimethylarginine contributes to the impaired response to erythropoietin in CKD-anemia. J Am Soc Nephrol 2017; 28: 2670-80.
35) Yamagishi S, Matsui T. Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy: friend or foe? Pharmaco Res 2011; 64: 187-94.
36) Yamagishi S, Ueda S, Matsui T, et al. Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties. Protein Pept Lett 2007; 14: 832-5.
37) Soro-Paavonen A, Zhang WZ, Venardos K, et al. Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase, J Hypertens 2010; 28: 780-8.
38) Ojima A, Ishibashi Y, Matsui T, et al. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end-product-induced protein arginine methyltransferase-1 expression. Am J Pathol 2013; 182: 132-41.
39) Ishibashi Y, Matsui T, Ueda S, et al. Irbesartan inhibits advanced glycation end-product-induced increase in asymmetric dimethylarginine level in mesangial cells through its anti-oxidative properties. Int J Cardiol 2014; 176: 1120-2.
40) Ando R, Ueda S, Yamagishi S, et al. Involvement of advanced...
glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction. Diab Vasc Dis Res 2013; 10: 436-41.

41) Kajikawa M, Nakashima A, Fujiwara N, et al. Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function. Diabetes Care 2015; 38: 119-25.

42) Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20: 1262-75.

43) Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.

44) Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 2009; 27: 165-97.

45) Meerwaldt R, Graaff R, Oomen PHN, et al. Simple non-invasive assessment of advanced glycation endproduct activity in patients with coronary artery disease. Circulation 2000; 102: 1000-6.

46) Kang SM, Chung N, Kim JY, et al. Relation of vasodilator response of the brachial artery to inflammatory markers in patients with coronary artery disease. Echocardiography 2002; 19: 661-7.

47) Honda A, Tahara N, Nitta Y, et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography/computed tomography is associated with endothelial dysfunction. Arterioscler Thromb Vasc Biol 2016; 36: 1980-8.

48) Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev 2007; 65: S253-9.

49) Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377: 1119-31.

50) Nakamura K, Yamagishi S, Adachi H, et al. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab Res Rev 2008; 24: 109-14.

51) Yanagisawa K, Asahiara J, Obara S, et al. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients. Diabetes Metab Res Rev 2014; 30: 693-700.

52) Tahara N, Yamagishi S, Takeuchi M, et al. Positive association between serum level of glycerolaldehyde-derived advanced glycation end products and vascular inflammation evaluated by [18F]fluorodeoxyglucose positron emission tomography. Diabetes Care 2012; 35: 2618-25.

53) Meerwaldt R, Graaff R, Oomen PHN, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004; 47: 1324-30.

54) Bos DC, de Ranitz-Greven WL, de Valk HW. Advanced glycation end products, measured as skin autofluorescence and diabetes complications: a systematic review. Diabetes Technol Ther 2011; 13: 773-9.

55) Yamagishi S, Fukami K, Matsui T. Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: a novel marker of vascular complications in high-risk patients for cardiovascular disease. Int J Cardiol 2015; 185: 263-8.

56) Nagano M, Fukami K, Yamagishi S, et al. Tissue level of advanced glycation end products is an independent determinant of high-sensitivity C-reactive protein levels in haemodialysis patients. Nephrol (Carlton) 2011; 16: 299-303.

57) Mulder DJ, de Boer JF, Graaff R, et al. Skin autofluorescence is inversely related to HDL anti-oxidative capacity in type 2 diabetes mellitus. Atherosclerosis 2011; 218: 102-6.

58) Della Corte V, Tuttolomondo A, Pecoraro R, et al. Inflammation, endothelial dysfunction and arterial stiffness as therapeutic targets in cardiovascular medicine. Curr Pharm Des 2016; 22: 4658-68.

59) Mozos I, Luca CT. Crosstalk between oxidative and nitrosative stress and arterial stiffness. Curr Vasc Pharmacol 2017; 15: 446-56.

60) Llauradó G, Ceperueto-Mallafré V, Vilardell C, et al. Advanced glycation end products are associated with arterial stiffness in type 1 diabetes. J Endocrinol 2014; 221: 405-13.

61) Bucala R, Makita Z, Vega G, et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994; 91: 9441-5.

62) Cai W, He JC, Zhu L, et al. High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients. Circulation 2004; 110: 285-91.

63) Ishibashi Y, Matsui T, Takeuchi M, et al. Rosuvastatin blocks advanced glycation end products-elicited reduction of macrophage cholesterol efflux by suppressing NADPH oxidase activity via inhibition of geranylgeranylation of Rac-1. Horm Metab Res 2011; 43: 619-24.

64) Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364: 127-35.

65) Yamagishi S, Yonekura H, Yamamoto Y et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem 1997; 272: 8723-30.

66) Okamoto T, Yamagishi S, Inagaki Y, et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002; 16: 1928-30.

67) Yamagishi S, Nakamura K, Matsui T, et al. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem 2006; 281: 20213-20.

68) Yamagishi S, Imaizumi T. Pericyte biology and diseases. Int J Tissue React 2005; 27: 125-35.

69) Moulton KS. Plaque angiogenesis and atherosclerosis. Curr Atheroscler Rep 2001; 3: 225-33.

70) Sedding DG, Boyle EC, Demandt JAF, et al. Vasa vasorum angiogenesis: key player in the initiation and progression of atherosclerosis and potential target for the treatment of cardiovascular disease. Front Immunol 2018; 9: 706.

71) Fujino Y, Attizzani GF, Tahara S, et al. Association of skin autofluorescence with plaque vulnerability evaluated by optical coherence tomography in patients with cardiovascular...
disease. Atherosclerosis 2018; 274: 47-53.
72) Yamagishi S, Fujimori H, Yonekura H, et al. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia 1998; 41: 1435-41.
73) Takenaka K, Yamagishi S, Matsui T, et al. Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr Neurovasc Res 2006; 3: 73-7.
74) Yamagishi SI, Matsui T. Anti-atherothrombogenic properties of PEDF. Curr Mol Med 2010; 10: 284-91.
75) Yamagishi S, Matsui T, Takenaka K, et al. Pigment epithelium-derived factor (PEDF) prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced glycation end products (AGEs). Diabetes Metab Res Rev 2009; 25: 266-71.
76) Ishibashi Y, Matsui T, Ueda S, et al. Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression. Cardiovasc Diabetol 2014; 13: 60.
77) Ishibashi Y, Matsui T, Yamagishi S. Apixaban exerts anti-inflammatory effects in mesangial cells by blocking thrombin/protease-activated receptor-1 system. Thromb Res 2014; 134: 1365-7.
78) Ishibashi Y, Matsui T, Fukami K, et al. Rivaroxaban inhibits oxidative and inflammatory reactions in advanced glycation end product-exposed tubular cells by blocking thrombin/protease-activated receptor-2 system. Thromb Res 2015; 135: 770-3.
79) Chen Q, Dong L, Wang L, et al. Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2. Biochem Biophys Res Commun 2009; 381: 192-7.
80) Ueda S, Yamagishi S, Matsui T, et al. Serum levels of advanced glycation end products (AGEs) are inversely associated with the number and migratory activity of circulating endothelial progenitor cells in apparently healthy subjects. Cardiovasc Ther 2012; 30: 249-54.
81) Schmidt-Lucke C, Rössig L, Fichtlscherer S, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005; 111: 2981-7.
82) Ueno H, Koyama H, Fukumoto S, et al. Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease. Metabolism 2011; 60: 453-9.
83) de Vos LC, Noordzij MJ, Mulder DJ, et al. Skin autofluorescence as a measure of advanced glycation end products deposition is elevated in peripheral artery disease. Arterioscler Thromb Vasc Biol 2013; 33: 131-8.
84) de Vos LC, Boersema J, Mulder DJ, et al. Skin autofluorescence as a measure of advanced glycation end products deposition predicts 5-year amputation in patients with peripheral artery disease. Arterioscler Thromb Vasc Biol 2015; 35: 1532-7.
85) Lapolla A, Piarrulli F, Sartore G, et al. Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care 2007; 30: 670-6.
86) Prasad A, Lane JR, Tsimikas S, et al. Plasma levels of advanced glycation end products are related to the clinical presentation and angiographic severity of symptomatic lower extremity peripheral arterial disease. Int J Angiol 2016; 25: 44-53.
87) Mulder DJ, van Haelst PL, Graaff R, et al. Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events. Neth Heart J 2009; 17: 162-8.
88) Meerwaldt R, Lutgers HL, Links TP, et al. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 2007; 30: 107-12.
89) Nin JW, Jorsal A, Ferreira I, et al. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 2 diabetes: a 12-year follow-up study. Diabetes Care 2011; 34: 442-7.
90) Kilhovd BK, Juutilainen A, Lehto S, et al. Increased serum levels of advanced glycation end products predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia 2007; 50: 1409-17.